Showing 5341-5350 of 9958 results for "".
- CAB Gel Reduces Lesions and Preserves Skin Tone in Skin of Colorhttps://practicaldermatology.com/news/cab-gel-reduces-lesions-and-preserves-skin-tone-in-skin-of-color/2474010/A post hoc analysis of pooled Phase 2 and Phase 3 clinical trial data suggests that clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% (CAB) gel is effective and well tolerated for the treatment of moderate to severe acne in Black patients.
- Study Links Psoriasis Gene Regulation to Spatial Genome Changeshttps://practicaldermatology.com/news/study-links-psoriasis-gene-regulation-to-spatial-genome-changes/2474007/Results from a new study in the Journal of Investigative Dermatology showed how changes in the 3D chromatin architecture of CD4+ T cells contribute to immune dysregulation in psoriasis. "In this study, the 3D genomic
- Study: Dermabrasion Trials Rarely Report Race or Skin Typehttps://practicaldermatology.com/news/study-dermabrasion-trials-rarely-report-race-or-skin-type/2474005/Most clinical trials studying dermabrasion have failed to report racial or skin-type demographics, according to a new systematic review. "Clinical trials that are racially homogenous or do not report race limit the generalizab
- Bimekizumab Trials 'Raise the Bar' for HS, Dr. Vivian Shi Sayshttps://practicaldermatology.com/news/Bimekizumab-Trials-Raise-Bar-HS-Dr-Vivian-Shi-Says/2473933/More than half of hidradenitis suppurativa (HS) patients treated with bimekizumab (BIMZELX, UCB) had no draining tunnels (DTs) at 2 years, and 63.6% reported no or mild skin pain, compared to 10.0% at baseline, according to new data presented at the 2025 American Academy of Dermatology (AAD) Annu
- Continuous Abrocitinib Use Linked to Better Long-Term AD Outcomes: Studyhttps://practicaldermatology.com/news/continuous-abrocitinib-use-linked-to-better-long-term-ad-outcomes-study/2473925/A new real-world study suggests that sustained abrocitinib treatment and adherence to the full 12-week induction phase improved outcomes and delay relapse in patients with moderate to severe atopic dermatitis (AD). "Although c
- No Link Between PCSK9 Inhibitors and Vitiligo Risk: Studyhttps://practicaldermatology.com/news/analysis-no-link-between-pcsk9-inhibitors-and-vitiligo-risk/2471859/New research published in the Journal of Investigative Dermatology shows no evidence linking PCSK9 inhibitors to an increased risk of vitiligo. Researchers exploring whether inhibiting PCSK9
- riSCC App Launched for Risk Stratification of cSCChttps://practicaldermatology.com/news/riSCC-App-Launched-Risk-Stratification-cSCC/2471817/The not-for-profit organization Skin Cancer Consortium Outcomes (SCOUT) announced it has launched riSCC, a data-driven clinician mobile app designed for risk stratification of cutaneous squamous cell carcinoma (cSCC) in clinical settings. SCOUT, founded in 2018, is committed to transformi
- Almirall Hosts 16th Skin Academyhttps://practicaldermatology.com/news/Almirall-Hosts-16th-Skin-Academy/2471810/Almirall held the 16th edition of its Skin Academy conference for healthcare professionals in the field of dermatology on March 22-23 at the Barcelona International Convention Center in Spain. The event featured a comprehensive program aimed at sharing state-of-the-art scientific knowledge
- Biologics Linked to Lower Infection Risk in Older Psoriatic Patients: Studyhttps://practicaldermatology.com/news/biologics-linked-to-lower-infection-risk-in-older-psoriatic-patients-study/2471809/Biologics targeting interleukin (IL)-12, IL-23, and IL-17 were associated with lower rates of serious infection in older adults with psoriatic disease, according to a cohort study using Ontario health data. The study, publishe
- Secukinumab Reduces Erosions in Psoriatic Arthritis Patientshttps://practicaldermatology.com/news/secukinumab-reduces-erosions-in-psoriatic-arthritis-patients/2471713/Secukinumab significantly reduced erosion progression in patients with psoriatic arthritis (PsA), according to findings from a phase 4 randomized, double-blind, placebo-controlled trial. The study evaluated the impact of the I